Peripheral Neuropathy Trial, Recruiting NCT06491082 Sponsor: Swami Rama Himalayan University Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06491082
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are receiving chemotherapy to treat a solid tumour (a type of cancer that forms a lump or growth in the body)
  • People who are over 18 years of age

Who may not be able to join:

  • People who are 18 years of age or younger
  • People who already have nerve damage (neuropathy) before starting the trial
  • People who have been diagnosed with a psychiatric (mental health) illness
  • People who are already taking medication to treat nerve pain or nerve damage
  • People who have had diabetes for more than 10 years
  • People who have kidney or liver disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Swami Rama Himalayan University
Registry
ClinicalTrials.gov
Start date
23 November 2022
Est. completion
20 August 2024

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Assessment of different type and severity of Neuropathy in Solid Cancer Patients Undergoing Chemotherapy using Total Neuropathy Score(TNS) and Nerve conduction velocity study; NOX4 Gene Expression in Blood of Solid Cancer Patients Undergoing Chemotherapy; Serum Vitamin D and Homocysteine Levels in Solid Cancer Patients Undergoing Chemotherapy; serum catalase and malondialdehyde level in solid cancer patients undergoing chemotherapy; Nerve conduction studies (NCS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov